Publications by authors named "Joachim Hofmann"
Article Synopsis
- The field of therapeutic antibodies, particularly bi- or multispecific antibodies, is expanding rapidly, especially for cancer treatment due to their ability to target multiple pathways.
- Designing and creating multispecific antibodies is complex and labor-intensive, starting with generating antibodies against specific targets and then combining their binding sites, as suitable configurations are hard to predict.
- The SpyTag-SpyCatcher technology allows for easier assembly of these multispecific antibodies by enabling separate production of tag and catcher proteins, and experiments have successfully created large multivalent antibodies containing up to seven building blocks while maintaining binding functionality.
The drug discovery process in the biopharmaceutical industry usually starts with the generation of plasmids coding for certain proteins. Due to advances in cloning techniques the generation of thousands of different plasmids is not a limiting factor anymore. The next step is the expression and evaluation of the proteins.
View Article and Find Full Text PDF